More annual reports from Nanollose Limited:
2023 ReportPeers and competitors of Nanollose Limited:
Scholar RockNanollose Limited 
ABN 13 601 676 377 
Annual Report 
30 June 2020 
1 
 
  
  
 
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
Corporate Directory 
Directors’ Report   
Auditor’s Independence Declaration 
Statement of profit or loss and other comprehensive income 
Statement of financial position 
Statement of changes in equity 
Statement of cash flows 
Notes to the financial statements 
Directors' declaration 
Independent auditor's report to the members of Nanollose Limited 
  3 
  4 
19 
20 
21 
22 
23 
24 
41 
42 
2 
  
  
 
 
 
 
  
 
Corporate Directory 
Directors 
 Wayne Best 
 Winton Willesee 
 Terence Walsh  
Heidi Beatty (appointed 8 July 2019) 
Gary Cass (resigned 8 July 2019) 
Managing Director                              Raffaele (Alfie) Germano 
Company Secretary 
 Erlyn Dale 
Stock exchange listing 
 Nanollose Limited shares are listed on the Australian Securities Exchange (ASX) 
(ASX code: NC6 and NC6O). 
Registered office 
Principal place of business 
Share register 
Auditor 
Solicitors 
 Suite 5 
 CPC 
 145 Stirling Highway 
 Nedlands WA 6009 
 Suite 5 
 CPC 
 145 Stirling Highway 
 Nedlands WA 6009 
 Automic Registry Services 
 Level 2 
 267 St Georges Terrace 
 Perth WA  6000 
 Phone: 08 9324 2099 
 RSM Australia Partners 
 Level 32 Exchange Tower, 2 The Esplanade 
 Perth WA  6000 
 Fairweather Corporate Lawyers 
 Unit 2, 589 Stirling Highway 
 Peppermint Grove WA 6011 
Website 
 www.nanollose.com 
3 
  
  
  
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
  
 
 
  
  
Nanollose Limited 
Directors’ Report 
30 June 2020 
The directors present their report, together with the financial statements of Nanollose Limited (referred to hereafter as the 
'Company') for the year ended 30 June 2020. 
Directors 
The following persons were directors of the Company during the whole of the financial year and up to the date of this report, 
unless otherwise stated: 
Wayne Best 
Winton Willesee 
Terence Walsh 
Heidi Beatty (appointed 8 July 2019) 
Gary Cass (resigned 8 July 2019) 
Raffaele (Alfie) Germano (Managing Director) 
Principal activities 
Nanollose Limited is a leading biotechnology company, commercialising scalable technology to create fibres and fabrics with 
minimal  environmental  impact.  During  the  financial  year,  the  principal  continuing  activities  of  the  Company  consisted  of 
research and development, and promotion of the Company’s microbial cellulose technology. The primary focus has been 
directed towards the development, scale up and ultimate commercialisation of the Company’s Plant-Free rayon fibre for use 
in textiles (nullarborTM) and non-woven applications (nufolium™).  
Dividends 
There were no dividends declared or paid during the financial year (2019: Nil).  
Operating Results 
During the year, the principal continuing activities of the Company consisted of research and development, and promotion 
of the Company’s nanocellulose technology.  
The loss for the Company after providing for income tax amounted to $1,235,489 (30 June 2019: $2,003,995). 
Review of Operations 
Nanollose Limited (ASX:NC6) is a leading biotechnology company, commercialising scalable technology to create fibres and 
fabrics with minimal environmental impact.  Nanollose uses an eco-friendly fermentation process to produce Tree-Free rayon 
fibres, which are primed to become an alternative to conventional tree-based rayon and cotton fibres. 
The Company has a number of proprietary technologies to convert wastes from the agricultural, food and beverage industries 
into unique eco-friendly rayon fibres for textiles, non-woven fabrics and other industrial applications.   
The Company is targeting the US$500 billion textile industry with an initial focus on the US$14.4 billion rayon market. 
Collaboration Agreement with Grasim 
In January 2020, Nanollose achieved a major milestone when the Company signed a Collaboration Agreement with Grasim, 
a  company  belonging  to  global  conglomerate,  Aditya  Birla  Group,  one  of  the  world’s  largest  rayon  manufacturers,  to 
exclusively develop, and commercialise Nanollose’s Tree-Free fibres including nullarbor™ and nufolium™.  
The Collaboration Agreement provides the Company with a world class and globally recognised industrial partner, with the 
ability to accelerate development, commercialisation and provide a manufacturing foundation for future textile and clothing 
brands  that  uptake  Nanollose’s  Tree-Free  fibres.    As  an  industrial  fibre  manufacturer,  Grasim  was  the  final  missing  link 
required to complete Nanollose’s waste to textile value chain. 
4 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Directors' report 
30 June 2020 
Despite global  lockdowns to contain  the spread  of COVID-19, the Company has continued  to advance the Collaboration 
Agreement with Grasim, by liaising with their R&D team and exchanging important technical information. New and improved 
samples of processed microbial cellulose were successfully shipped from Nanollose to Grasim in June 2020 for trial fibre 
spinning. 
Over the past months, the Company has also increased capabilities and capacity at its WA facilities, in part to support the 
Grasim Collaboration. This has resulted in improvements and refinements to the integration and efficiency of its processes, 
to  transform  waste  material  into  microbial  cellulose  (“MC”)  suitable  for  conversion  into  nullarbor™  fibre.  These  process 
improvements will assist greatly during the upcoming scale-up phase. In addition, Nanollose has recently been exploring an 
alternative waste stream sourced from several  local  companies  in  WA, for its potential to  produce  MC, with encouraging 
early results. 
Non-Woven Fibres and Codi Co-Operation Agreement 
In July 2019, Nanollose’s Tree-Free rayon fibre was successfully converted into a non-woven fabric, in what the Company 
believes to be another world first sustainable material. The success of this trial quickly resulted in a Cooperation Agreement 
with Codi International BV, which is part of the Codi Group (“Codi”), a global leader in the development, manufacturing and 
marketing of high-quality personal care wipes.  
Under  the  Co-Operation  Agreement,  both  companies  will  exclusively  work  together  in  developing  commercially  viable 
consumer  wipe  products  using  Nanollose’s  Tree-Free  non-woven  fibres.  Codi’s  extensive  technical  and  commercial 
understanding, along with its ability to prototype and test products, will assist Nanollose in commercialising its Tree-Free 
rayon  fibre  for  this  market  sector.    A  growing  application  base  in  the  healthcare  and  personal  care  industry,  along  with 
increasing demand from the automotive industry, are some of the factors propelling market growth in the non-woven sector. 
Corporate 
The diversity and independence of the Board was increased in July 2019 with the appointment of independent non-executive 
director Heidi Beatty. Ms Beatty has 20 years  ’experience developing consumer and healthcare products and is the founder 
of Crown Abbey, an innovation consultancy company operating in the US and Europe that helps consumer and healthcare 
clients identify new technologies and provides support through to launch. 
On 11 November 2019 the Company received a R&D Tax Incentive Rebate of $461,847 from the ATO for R&D undertaken 
in the 2018-2019 financial year. 
On 11 May 2020 the Company raised $376,097 from a 2:5 rights issue at $0.024 per share to existing shareholders. On 21 
May 2020 the Company raised an additional $343,903 by placing the shortfall from the rights issue. 
In light of the challenges and delays caused by COVID-19, the Company’s directors took a reduction in cash remuneration. 
This, combined with a significant reductions in the cash component of executive salaries and other savings, has reduced the 
Company’s monthly expenses considerably. 
Impact of Covid-19 Global Pandemic  
The  impact  of  the  Coronavirus  (COVID-19)  pandemic  is  ongoing  and  whilst  it  has  had  no  direct  financial  impact  for  the 
Company up to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting 
date.  
The  situation  is  rapidly  developing  and  is  dependent  on  measures  imposed  by  the  Australian  Government  and  other 
countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that 
may be provided. 
Throughout temporary lockdowns to control the spread of COVID-19, the Company’s operations in Western Australia (“WA”) 
have continued unaffected. While the Company’s overseas partners, Grasim and Hainan Yeguo Foods Co., Ltd (“Hainan 
Yeguo Foods”) have been impacted by lockdowns, however the agreements have continued as the Company progresses to 
commercialise its tree-free fibres. 
5 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Directors' report 
30 June 2020 
As  stated  earlier,  during  the  lockdown  period,  the  Company  has  worked  diligently  to  advance  the  Grasim  Collaboration 
Agreement, to exchange important technical information with Grasim’s R&D team. 
It was also possible for the Company to continue to liaise with Hainan Yeguo Foods even during the lockdown period, to 
refine the desired technical specifications for its MC. Hainan Yeguo Foods is operational again and have recently provided 
the Company with a new and improved sample of MC for testing and trial processing as a prelude to scale-up. 
While the pandemic has seen paradigm shifts in many industries, it is encouraging to see that it has only strengthened the 
fashion  industry’s  commitment  to  sustainability,  with  Nanollose’s  Tree-Free  fibres  ideally  placed  to  assist  the  industry  in 
meeting that commitment. 
Significant changes in the state of affairs  
Other than detailed in the review of operations, there were no other significant changes in the state of affairs of the Company 
during the financial year. 
Matters subsequent to the end of the financial year 
No  matter  or  circumstance  has  arisen  since  30  June  2020  that  has  significantly  affected,  or  may  significantly  affect  the 
Company's operations, the results of those operations, or the Company's state of affairs in future financial years. 
Likely developments and expected results of operations  
The Company has made significant progress over the past year as it positions itself at the forefront of commercially viable, 
eco-friendly  fibre  alternatives  for  the  fashion  and  textile  industries.  With  the  Collaboration  Agreement  with  Grasim,  the 
Company envisages that the next year will see nullarbor™ and nufolium™ fibres move through the development phase and 
into commercial trials. With commercial quantities of fibre in hand, the Company will be well placed to select a small number 
of partners to transform fibre into highly desirable consumer products. 
Environmental regulation 
The Company is not subject to any significant environmental regulation under Australian Commonwealth or State law. 
6 
 
  
  
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Directors' report 
30 June 2020 
Information on directors 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
 Wayne Best 
 Executive Chairman 
 BSc (Honours), PhD, DIC, FRACI, GAICD 
 Wayne has 36 years’ experience in organic chemistry both in academia, government 
and industry. Wayne obtained his BSc (Hons) and PhD in Organic Chemistry from The 
University of Western Australia. He then spent two years at Imperial College in the UK 
where he obtained a DIC, followed by a year at the Australian National University in 
Canberra. He then took up a position with ICI Australia’s Research Group in Melbourne 
for four and a half years which included a secondment to ICI Agrochemicals’ in the UK. 
Following  ICI,  Wayne  returned  to  Western  Australia  and  spent  ten  years  at  the 
Chemistry Centre (WA) where he was responsible for the formation and running of the 
Medicinal & Biological Chemistry Section which undertook collaborative R&D into drug 
discovery and contract synthesis for the drug discovery and pharmaceutical industries. 
He then founded Epichem Pty Ltd, a contract research and drug discovery Company, 
which he managed for 14 years before moving to Nanollose. He is currently Epichem’s 
non-executive chairman. Wayne is a Fellow of the Royal Australian Chemical Institute 
and  has  held  appointments  as  an  Adjunct  Associate  Professor  at  both  Murdoch 
University and The University of Western Australia. He is also a Graduate Member of 
the Australian Institute of Company Directors and has served as a Director for several 
listed and unlisted biotechnology companies. 
Other current directorships: 
Former directorships (last three 
years): 
Interests in shares: 
Interests in options: 
Contractual rights to shares: 
 None 
 Pharmaust Limited 
 8,285,002 ordinary shares 
2,000,000 Class C Performance Rights 
 1,290,476 Class A options  
1,404,465 NC6O listed options 
 None 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
 Alfie Germano 
 Managing Director  
 Diploma - FDTS 
 Mr Germano is a creative achiever who strives for the balance of art and science in 
product and process.  He is a 30-year veteran in the global textile industry sector.  Alfie 
obtained his Fashion Design and Textile Science Diploma from the Bentley College of 
Technical  and  Further  Education  in  Perth,  Western  Australia.    After  working  for  his 
family garment manufacturing company, he moved to Hong Kong where he spent 24 
years in the garment industry as a leader of large scale global product development, 
sourcing and retail operations.  He held Vice President and Director positions at GAP 
Inc, VF Corporation, Liz Claiborne Inc, Fila Inc and Carter’s Inc.  Alfie has travelled the 
world extensively with postings in the USA, Japan and China.  Alfie relocated his family 
to  Perth  in  2016  and  is  enjoying  the  “green-change”  in  Australia.    He  is  passionate 
about sustainability, strategy, performance, metrics, process and product. 
Other current directorships: 
Former directorships (last three 
years): 
Interests in shares: 
Interests in options: 
Contractual rights to shares: 
None 
 None 
 700,000 ordinary shares 
250,000 Class A Performance Rights 
 250,000 Class B Performance Rights 
2,000,000 Class C Performance Rights 
 1,100,000 Class C options 
 1,100,000 Class D options 
 125,000 NC6O listed options 
 None 
7 
 
  
  
 
  
 
 
  
 
 
 
 
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
Other current directorships: 
Former listed company 
directorships (last three years): 
Interests in shares: 
Interests in options: 
Contractual rights to shares: 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
 Winton Willesee 
 Non-Executive Director 
 BBus, DipEd, PGDipBus, MCom, FFin, CPA, GAICD, FGIS/FCIS 
 Mr Willesee is an experienced corporate professional with a broad range of skills and
experience  strategy,  company  development,  corporate  governance,  company  public 
listings,  merger  and acquisition transactions and corporate finance.  Mr Willesee  has 
considerable experience with ASX listed and other companies over a broad range of 
industries, having held directorships, chairmanships and company secretarial positions 
with  a  number  of  ASX-listed  companies  over  many  years.  Mr  Willesee  holds  formal 
qualifications in Commerce, Economics and Finance, Accounting, Applied Finance and 
Investment,  Applied  Corporate  Governance  and  Education.  He  is  a  Fellow  of  the 
Financial Services Institute of Australasia, the Governance Institute of Australia and the 
Institute  of  Chartered  Secretaries  and  Administrators,  Graduate  of  the  Australian 
Institute of Company Directors and a Member of CPA Australia.  
New  Zealand  Coastal  Seafoods  Limited,  MMJ  Group  Holdings  Limited,  Neurotech 
International Limited and eSense Lab Ltd 
 Ding Sheng Xin Finance Co Limited and Kopore Metals Limited  
 7,830,000 ordinary shares 
 1,290,476 Class A options 
1,398,215 NC6O listed options 
 None 
 Terence Walsh 
 Non-Executive Director 
 LLB 
 Terry  is  a  senior  commercial  lawyer  and  manager  with  more  than  20  years  of 
experience  in  project  development,  mining  and  general  commercial  law.   He  initially 
worked with leading law firms in Perth and Sydney before moving in house, where he 
has worked as the General Counsel of Hancock Prospecting Pty Ltd and prior to that 
as a Corporate Counsel with Rio Tinto Ltd.  In these roles he has been involved with 
the legal and commercial aspects associated with the development and operation of 
technology and mining projects.   
Other current directorships: 
Former directorships (last three 
years): 
Interests in shares: 
Interests in options: 
Contractual rights to shares: 
 Structural Monitoring Systems PLC 
 Hazer Group Limited 
 700,000 ordinary shares 
 1,500,000 Class A options 
125,000 NC6O listed options 
 None 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
Other current directorships: 
Former directorships (last three 
years): 
Interests in shares: 
Interests in options: 
Contractual rights to shares: 
 Heidi Beatty 
 Non-Executive Director (appointed 8 July 2019) 
 BSc 
 Heidi Beatty, founder of Crown Abbey Ltd is a scientist and innovator who has 20 years’ 
experience  developing  consumer  and  health  care  products.    After  gaining  a  BSc  in 
Chemistry from the University of York UK, Heidi worked with Johnson & Johnson for 
10 years in Europe and the US.  In 2015 Heidi founded Crown Abbey Ltd, a consultancy 
launches,  combining  Project 
company 
Management and Product Development across Consumer and Healthcare categories.
 None 
 None 
that  supports  clients 
their  project 
in 
 Nil 
 Nil 
 None 
8 
 
  
  
 
 
  
 
  
 
  
Nanollose Limited 
Directors' Report 
30 June 2020 
Name: 
Title: 
Qualifications: 
Experience and expertise: 
 Gary Cass 
 Executive Director (resigned 8 July 2019) 
 BSc 
 Mr Cass has a BSc in Agricultural Sciences specialising in microbiology and over 20 
years’  experience  working  with  microbial  cellulose.  In  addition  to  his  expertise  in 
microbiology he has a broad theoretical and practical knowledge across the biological 
sciences including environmental conversation and molecular biotechnology. Mr Cass 
has  published  in  scientific  journals  and  run  international  bio-science  workshops  in 
Australia and overseas. He has been a key collaborator with numerous international 
arts and sciences projects, including Fermented Fashion, the first dresses in the world 
made  from  wine  and  beer  that  have  been  exhibited  around  the  world  including  the 
Venice Biennale (fringe), Trinity College Science Gallery, Ireland and the Signature Art 
Prize in Singapore. 
 None 
 None 
Other current directorships: 
Former directorships (last three 
years): 
Interests in shares as at the date of 
resignation: 
Interests in options as at the date of 
resignation: 
Contractual rights to shares: 
5,142,857 ordinary shares 
 1,190,476 Class A options 
1,285,715 NC6O listed options 
 None 
'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all 
other types of entities unless otherwise stated. 
'Former directorships (last three years)' quoted above are directorships held in the last three years for listed entities only and 
excludes directorships of all other types of entities, unless otherwise stated. 
Company secretary 
Miss  Dale  is  an  experienced  corporate  professional  with  a  broad  range  of  corporate  governance  and  capital  markets 
experience,  having  been  involved  with  several  public  company  listings,  merger  and  acquisition  transactions  and  capital 
raisings for ASX-listed companies across a diverse range of industries.   
Miss Dale began her career in corporate recovery and restructuring at Ferrier Hodgson and is now the Managing Director of 
corporate services firm, Azalea Consulting, which provides outsourced company secretarial, accounting and administration 
services to a portfolio of ASX-listed companies.  
Miss  Dale  holds  a  Bachelor  of  Commerce  (Accounting  and  Finance)  and  a  Graduate  Diploma  in  Applied  Corporate 
Governance. She is a member of the Governance Institute of Australia/Chartered Secretary. 
Meetings of directors 
The number of meetings of the Company's Board of Directors ('the Board') and of each Board committee held during the 
year ended 30 June 2020, and the number of meetings attended by each director were: 
Wayne Best 
Winton Willesee 
Terence Walsh 
Alfie Germano 
Gary Cass 
Heidi Beatty 
  Attended 
Held 
5 
5 
5 
5 
- 
5 
5 
5  
5 
5  
 - 
5 
Held: represents the number of meetings held during the time the director held office. 
9 
 
  
  
  
 
  
 
 
  
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Remuneration report (audited) 
The remuneration report details the key management personnel remuneration arrangements for the Company, in accordance 
with the requirements of the Corporations Act 2001 and its Regulations. 
Key management personnel are those persons having authority and responsibility for planning, directing and controlling the 
activities of the Company, directly or indirectly, including all directors. 
The remuneration report is set out under the following main headings: 
● 
● 
● 
● 
● 
 Principles used to determine the nature and amount of remuneration 
 Details of remuneration 
 Service agreements 
 Share-based compensation 
 Additional disclosures relating to key management personnel 
Principles used to determine the nature and amount of remuneration 
The  objective  of  the  Company’s  executive  reward  framework  is  to  ensure  reward  for  performance  is  competitive  and 
appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives 
and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of 
reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward 
governance practices: 
● 
● 
● 
● 
 competitiveness and reasonableness 
 acceptability to shareholders 
 performance linkage / alignment of executive compensation 
 transparency 
The Board fulfilling the role of the Nomination and Remuneration Committee is responsible for determining and reviewing 
remuneration arrangements for its directors and executives. The performance of the Company depends on the quality of its 
directors and executives. The remuneration philosophy is to attract, motivate and retain high performance and high quality 
personnel. 
The Board has structured an executive remuneration framework that is market competitive and complementary to the reward 
strategy of the Company. 
The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it 
should seek to enhance shareholders' interests by: 
● 
● 
● 
 having value creation and capital growth in advance of economic profit as a core component of plan design; 
 focusing on sustained growth in shareholder wealth, consisting of growth in share price and eventually dividends, and 
delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value; 
and 
 attracting and retaining high calibre executives. 
Additionally, the reward framework should seek to enhance executives' interests by: 
● 
● 
● 
 rewarding capability and experience; 
 reflecting competitive reward for contribution to growth in shareholder wealth; and 
 providing a clear structure for earning rewards. 
In  accordance  with  best  practice  corporate  governance,  the  structure  of  non-executive  director  and  executive  director 
remuneration is separate. 
10 
 
  
  
  
  
  
 
  
  
  
 
  
 
  
  
Nanollose Limited 
Directors' Report 
30 June 2020 
Non-executive directors’ remuneration 
Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' 
fees  and  payments  are  reviewed  from  time  to  time  by  the  Board  fulfilling  its  role  as  the  Nomination  and  Remuneration 
Committee. The Board may, from time to time, receive advice from independent remuneration consultants to ensure non-
executive directors' fees and  payments are appropriate and in  line  with the market. The chairman's fees are determined 
independently to the fees of other non-executive directors based on comparative roles in the external market. The chairman 
is not entitled to vote on the determination of his own remuneration. Given the nature of the Company and the more hands-
on role the non-executive directors’ play in the operations of the Company non-executive directors may receive share options 
or other incentives. 
ASX  listing  rules  require  the  aggregate  non-executive  directors'  remuneration  be  determined  periodically  by  a  general 
meeting. The most recent determination was via a resolution of all shareholders on 5 June 2016, where the shareholders 
approved a maximum annual aggregate remuneration of $500,000. 
Executive directors’ remuneration 
The Company aims to reward executives based on their position and responsibility, with a level and mix of remuneration 
which has both fixed and variable components. 
The executive remuneration and reward framework has four components: 
● 
● 
● 
● 
 base pay and non-monetary benefits 
 short-term performance incentives 
 share-based payments 
 other remuneration such as superannuation and long service leave 
The combination of these comprises the executive's total remuneration. 
Fixed remuneration, consisting  of base salary, superannuation and non-monetary benefits, are reviewed regularly by the 
Board fulfilling the role of Nomination and Remuneration Committee based on the overall performance of the Company and 
comparable market remunerations. 
Executives may receive their fixed remuneration in the form of cash or other benefits where it does not create any additional 
costs to the Company and provides additional value to the executive. 
The short-term incentives ('STI') program has yet to be finalised.  Once adopted it will be designed to align the targets of 
Company with the performance hurdles of executives. STI payments will be granted to executives based on specific annual 
targets and key performance indicators ('KPI's') being achieved.   
The long-term  incentives ('LTI') include equity-based  payments. Equity securities are awarded to executives with vesting 
conditions and expiry dates aligned to the Company’s business plans and targets. The details of the current vesting conditions 
and targets are as follows and further detailed in the section on service agreements found below.  
Options 
The Options vest on the achievement of the following milestones: 
Class B - The Company enters into a commercial agreement;(lapsed on 30 September 2019) 
1. 
2. 
to exploit one of the Company’s two existing patents (AU2016904456 and AU2017901318); and 
receives $1 million of gross revenue under that agreement. 
Class C - The Company enters into a commercial agreement; 
1. 
2. 
to exploit a second technology or patent held by the Company (other than the patent the subject of Milestone 1); and  
receives $5 million of gross revenue under that agreement. 
Class D - The Company enters into a commercial agreement; 
1. 
2. 
to exploit a third technology or patent held by the Company; and 
receives $10 million of gross revenue under that agreement. 
All class C and D Options vest in the event of a ‘takeover event’. 
11 
 
  
  
  
  
  
 
  
  
  
  
 
 
 
 
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Performance Rights 
Pursuant  to  Shareholder  approval  at  the  Company’s  2019  Annual  General  Meeting  held  on  24  October  2019.  Mr  Alfie 
Germano  was  issued  2,000,000  Class  C  Performance  Rights  and  Dr  Wayne  Best  was  issued  2,000,000  Class  C 
Performance Rights.  The Performance Rights will, at the election of the holder, vest and convert into one share along with 
one option (NC6O)  if, before 31 December 2020, the Company enters into a commercial agreement relating to the licencing 
of the Company’s intellectual property and receives $1,000,000 of gross revenue under this agreement or a Takeover Event 
occurs. 
A "Takeover Event" means a takeover bid for the Company pursuant to Chapter 6 of the Corporations Act where at least 
50% of the holders of ordinary shares accept the bid and such bid is free of conditions or a court grants an order approving 
a compromise or scheme where the ordinary shares are either cancelled or transferred to a third party (not being a scheme 
of arrangement simply for the purposes of a corporate restructure).  
Company performance and link to remuneration 
Remuneration for certain individuals is directly linked to the performance of the Company. Each key management personnel 
holds equity securities designed to incentivise them to drive the Company’s performance in line with its business plans.  
A portion of any cash bonus that may be paid to executives will be directly linked to the achievement of goals designed to 
align with the Company’s performance. 
Details of remuneration 
Details of the remuneration of key management personnel of the Company during the year ended 30 June 2020 are set 
out in the following tables. 
The key management personnel of the Company consisted of the following directors of Nanollose Limited: 
-  Wayne Best (Executive Chairman) 
-  Winton Willesee (Non-Executive Director) 
-  Gary Cass (Executive Director) 
-  Terence Walsh (Non-Executive Director)  
-  Alfie Germano (Managing Director) 
-  Heidi Beatty (Non-Executive Director) 
Changes since the end of the reporting period: 
-  Gary Cass resigned as Executive Director on 8 July 2019 
-  Heidi Beatty was appointed as a Non-Executive Director on 8 July 2019 
Cash salary 
and fees 
Super- 
annuation 
Annual Leave 
Equity-settled 
Shares 
$ 
$ 
$ 
$ 
Equity-settled 
Performance 
rights 
$ 
Total 
Fixed 
remunera
tion 
Incentive 
$ 
% 
% 
2020 
Executives: 
Wayne Best 
        172,500 
        16,625 
          18,174 
           2,500 
        114,070 
       323,869 
65% 
35% 
Gary Cass 
          91,612 
          7,714 
                   - 
                  - 
                   - 
         99,326 
100% 
- 
Alfie Germano 
        172,500 
        16,625 
          13,293 
           2,500 
        121,468             
       326,386 
87% 
37% 
Non-executives: 
Winton Willesee 
          33,833  
                 - 
                   - 
           1,167 
                  - 
        35,000 
100% 
Terence Walsh 
          33,839 
                 - 
Heidi Beatty 
          33,175 
                 - 
                   - 
                   - 
           1,161 
                  - 
        35,000 
100% 
           1,166                         - 
        34,341 
100% 
- 
- 
- 
Total 
        537,459 
        40,964 
          31,467 
           8,494 
        235,538 
      853,922 
12 
 
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Directors' Report 
30 June 2020 
2019 
Executives: 
Cash salary 
and fees 
Super-
annuation 
Annual Leave 
Equity-settled 
Shares 
$ 
$ 
$ 
$ 
Equity-settled 
Performance 
rights 
$ 
Total 
Fixed 
remunera
tion 
Incentive 
$ 
% 
% 
Wayne Best 
        242,677 
          21,375 
                 - 
           - 
                  - 
        264,052 
100% 
Gary Cass 
        170,626 
          15,200 
                 - 
          - 
                  - 
        185,826 
100% 
- 
- 
Alfie Germano 
        239,336 
          21,375 
                 - 
          - 
         39,178 
        299,889 
87% 
13% 
Non-executives: 
Winton Willesee 
          35,000  
                   - 
                 - 
         - 
                  - 
          35,000 
100% 
Terence Walsh 
          35,007 
                   - 
                 - 
        - 
                  - 
          35,007 
100% 
        722,646 
          57,950 
                 - 
        - 
         39,178 
         819,774 
- 
- 
Service agreements 
Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details 
of these agreements are as follows: 
Name: 
Title: 
Agreement commenced: 
Term of agreement: 
Details: 
Name: 
Title: 
Agreement commenced: 
Term of agreement: 
Details: 
 Alfie Germano 
 Managing Director 
 20 March 2017  
 No fixed term 
 Originally  with  a  base  Salary  of  $225,000  per  annum  plus  superannuation,    on  1 
September 2019 the base salary was amended to $165,000 for a period of 12 months 
for  which  Mr  Germano  (or  his  nominee)  was  issued  with  2,000,000  Class  C 
Performance  Rights  and  from  1  May  2020  the  base  salary  was  reduced  a  further 
$15,000 to $150,000 for which the Company proposes to seek shareholder approval 
for the issue of shares in lieu of the May 2020 $15,000 per annum reduction. In previous 
periods Mr Germano (or his nominee) has been issued with 500,000 Shares in lieu of
accrued  salary,  along  with  500,000  Performance  Rights  (Class  A  and  B),  each  with 
vesting  conditions  that  have  been  satisfied.  The  Agreement  may  be  terminated  by 
either party on 3 months’ notice, and there is a 12 month non-solicitation period upon 
any termination of the Agreement.  
 Wayne Best 
 Executive Chairman 
 9 April 2018 
 No fixed term 
 Originally with a base salary of $225,000 per annum plus superannuation, on 1 
September 2019 the base salary was amended to $165,000 for a period of 12 months 
for which Mr Best (or his nominee) was issued with 2,000,000 Class C Performance 
Rights and from 1 May 2020 the base salary was reduced a further $15,000 to 
$150,000 for which the Company proposes to seek shareholder approval for the issue 
of shares in lieu of the May 2020 $15,000 per annum reduction.  The Agreement may 
be terminated by either party on 3 months’ notice and there is a 12 month non-
solicitation period upon any termination of the Agreement.   
13 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Name: 
Title: 
Agreement commenced: 
Term of agreement: 
Details: 
 Gary Cass 
 Executive Director (resigned 8 July 2019) 
 11 June 2018 
 No fixed term 
 Base salary of $160,000 per annum plus superannuation with no separate Director’s 
fee  payable  from  the  commencement  of  the  Agreement.    Mr  Cass  gave  notice  in 
October  2019  and  ceased  with  the  Company  shortly  afterwards.  The  Agreement 
included a 12 month non-solicitation period following termination of the Agreement.  
Key management personnel have no entitlement to termination payments in the event of removal for misconduct. 
Share-based compensation 
There were no options issued to directors and other key management personnel as part of compensation during the year 
ended 30 June 2020. 
Pursuant  to  Shareholder  approval  at  the  Company’s  2019  Annual  General  Meeting  held  on  24  October  2019.  Mr  Alfie 
Germano  was  issued  2,000,000  Class  C  Performance  Rights  and  Dr  Wayne  Best  was  issued  2,000,000  Class  C 
Performance Rights.  The Performance Rights vest on the achievement of certain milestones by 31 December 2020 and 
upon vesting, each Class C Performance Right will convert into one ordinary share and one option (exercise price of 30 cents 
and 31 December 2020 expiry date). 
In previous periods, in accordance with his employment contract, 500,000 ordinary shares were issued to Mr Alfie Germano 
in lieu of his accrued salary at the time of the ASX listing. Mr Alfie Germano was also issued 500,000 performance rights all 
of which have now vested. 
Additional information 
The loss of the Company for the five years to 30 June 2020 are summarised below: 
Sales revenue 
EBITDA 
EBIT 
Loss after income tax 
2020 
$ 
                  - 
  (1,187,793) 
  (1,241,318) 
  (1,235,489) 
2019 
$ 
                  - 
  (2,022,299) 
  (2,054,457) 
  (2,003,995) 
2018 
$ 
                 -  
   2017 
   $ 
               -  
(1,776,703)  
(1,783,135)  
(1,730,214)  
(817,432)  
(817,916)  
(820,346)  
     2016 
    $ 
         11,630  
(9,790)  
(9,907)  
(9,907)  
The factors that are considered to affect total shareholders return ('TSR') are summarised below. Given the Company listed 
during the financial year, no comparative information is available. The Company’s official listing date was 18 October 2017. 
Share price at financial year end ($)  
Total dividends declared (cents per share) 
Basic loss per share (cents per share) 
   0.04 
           - 
      1.57 
0.05 
     - 
2.67 
0.13 
    - 
2.57 
            - 
            - 
       1.82 
2020 
2019 
2018 
2017 
14 
 
  
  
 
  
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
  
 
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Additional disclosures relating to key management personnel 
Shareholdings 
The number of shares in the Company held during the financial year by each director and other members of key management 
personnel of the Company, including their personally related parties, is set out below: 
  Balance at     Received  
as part of  
the start of    
the year 
  remuneration  Additions 
Disposal on 
resignation 
Balance at  
the end of  
the year 
Ordinary shares 
Wayne Best 
Winton Willesee 
Gary Cass 
Terence Walsh 
Alfie Germano 
Heidi Beatty 
Total 
Option holdings 
   5,917,858                    - 
      5,592,857                    - 
      5,142,857                    - 
         500,000                    - 
          500,000                    - 
-                   - 
  17,653,572                    - 
      2,367,144                   - 
                 - 
      2,237,143            
  (5,142,857) 
                 - 
         200,000                   - 
                 - 
         200,000         
                 - 
    - 
      5,004,287             
  (5,142,857) 
  8,285,002  
  7,830,000  
                -  
     700,000  
        700,000  
                   - 
17,515,002  
The  number  of  options  over  ordinary  shares  in  the  Company  held  during  the  financial  year  by  each  director  and  other 
members of key management personnel of the Company, including their personally related parties, is set out below: 
Options over ordinary shares 
Wayne Best 
Winton Willesee 
Gary Cass 
Terence Walsh 
Alfie Germano 
Heidi Beatty 
Total 
Performance Rights holdings 
Balance at  
the start of    
the year 
Issued 
Expired/  
disposal on  
Exercised     resignation 
Balance at  
the end of  
the year 
      2,694,941                 - 
      2,688,691                 - 
      2,476,191                 - 
      1,625,000                 - 
      3,425,000                 - 
                    -                 - 
    12,909,823                 - 
             - 
             - 
             - 
             - 
             - 
             - 
             - 
      2,694,941 
                 - 
                 - 
      2,688,691 
  (2,476,191)                      - 
      1,625,000 
                 - 
  (1,100,000)        2,325,000 
                - 
                    - 
  (3,576,191)        9,333,632 
The number of performance rights in the Company held during the financial year by each director and other members of key 
management personnel of the Company, including their personally related parties, is set out below: 
Rights to Ordinary shares 
Wayne Best 
Winton Willesee 
Gary Cass 
Terence Walsh 
Alfie Germano 
Heidi Beatty 
Total 
  Balance at    
the start of    
the year 
Issued 
  Converted 
Expired/  
forfeited/  
other 
  Balance at  
the end of  
the year 
    2,000,000 
                   - 
                  - 
                   - 
                  - 
                   - 
                   - 
                  - 
        500,000      2,000,000 
                  - 
        500,000       4,000,000 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
                  - 
     2,000,000 
                - 
                - 
                - 
      2,500,000 
                    - 
      4,500,000 
15 
 
  
  
  
 
  
  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
  
  
 
 
 
  
 
  
 
 
  
 
  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
  
  
  
 
 
 
 
  
 
Nanollose Limited 
Directors' Report 
30 June 2020 
Other transactions with key management personnel and their related parties during the financial year 
(i) Receivable from and payable to key management personnel and their related parties are as follows: 
The following balances are outstanding at the reporting date in relation to transactions with key management personnel and 
their related parties: 
Payable to Epichem Pty Ltd (director related entity of Wayne Best) 
Payable to Valle Corporate Pty Ltd (director related entity of Winton 
Willesee) 
Payable to Azalea Consulting Pty Ltd (director related entity of Winton 
Willesee) 
(ii) Transactions with key management personnel and their related parties 
  2020 
     $ 
  25,260 
    4,000 
  2019 
     $ 
  16,375 
    2,200 
  10,991 
    5,995 
Payments to Epichem Pty Ltd (director related entity of Wayne Best) of $153,592 (2019: $186,457) for research consultancy 
fees. As at the date of this report, Epichem is no longer a director related entity of Wayne Best. 
Payments to Valle Corporate Pty Ltd (director related entity of Winton Willesee) of $20,000 (2019: $22,000) for bookkeeping 
and financial reporting services fees. 
Payments to Azalea Consulting Pty Ltd (director related entity of Winton Willesee) of $59,955 (2019: $65,077) for corporate 
services fees including company secretarial services, and front and registered office services. 
All transactions were made on normal commercial terms and conditions and at market rates. 
Voting and comments made at the Company's 2019 Annual General Meeting ('AGM') 
At the AGM held on 24 October 2019, the Company received votes representing 16,008,785 shares in favour of  the adoption 
of the remuneration report put to shareholders for the financial year ended 30 June 2019.  This represented 96.3% of the 
votes cast at the AGM. 
This concludes the remuneration report, which has been audited. 
Shares 
As at the date of this report, there are 105,749,991 (2019: 74,999,993) fully paid ordinary shares on issue. 
Shares under option 
Unissued ordinary shares of Nanollose Limited under option at the date of this report are as follows: 
   Date of issue 
Class of option 
No. of Options 
Exercise price 
Expiry date 
   4 August 2016 
   5 April 2017 
   5 April 2017 
   5 April 2017 
   21 April 2017 
   21 June 2017 
   21 June 2017 
   25 May 2018 
   17 August 2018 
   21 May 2020 
   Total 
Class A 
Class A 
Class C 
Class D 
Class A 
Class C 
Class D 
         NC6O 
         NC6O 
      NC6OPT1 
      21,000,000 
        1,450,000 
           900,000 
           900,000 
        1,333,333 
           200,000 
           200,000 
      14,505,733 
        4,244,266 
        1,000,000 
      45,733,332 
$0.30 
$0.30 
$0.30 
$0.40 
$0.30 
$0.30 
$0.40 
         $0.30 
         $0.30 
         $0.10 
31 December 2020 
31 December 2020 
30 September 2020 
30 September 2021 
31 December 2020 
30 September 2020 
30 September 2021 
31 December 2020 
31 December 2020 
31 May 2023 
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of 
the Company or of any other body corporate. 
16 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
  
Nanollose Limited 
Directors' Report 
30 June 2020 
Performance Rights 
Performance rights of Nanollose Limited at the date of this report are as follows: 
Date of issue 
Class of 
performance 
rights 
No. of 
performance 
rights 
10 August 2017 
Class A 
       250,000 
10 August 2017 
Class B 
       250,000 
24 October 2019 
Class C 
   4,000,000 
Service condition 
Vesting date 
18 October 2018 
18 October 2019 
31 December 2020 
Each  Class  A  performance  right  will,  at  the 
election of the holder, vest and convert into one 
share upon satisfaction of the service condition 
as being engaged as the Managing Director for 
the period of 12 months after the Company lists 
on ASX. 
Each  Class  B  performance  right  will,  at  the 
election of the holder, vest and convert into one 
share upon satisfaction of the service condition 
as being engaged as the Managing Director for 
the period of 24 months after the Company lists 
on ASX. 
Each  Class  C  performance  right  will,  at  the 
election of the holder, vest and convert into one 
share  if,  before  31  December  2020,  the 
Company enters into a commercial agreement 
relating  to  the  licencing  of  the  Company’s 
intellectual property and receives $1,000,000 of 
gross  revenue  under  this  agreement  or  a 
Takeover Event occurs. 
Total 
   4,500,000 
The Class A and Class B performance rights have vested, but have not yet been exercised and converted to Ordinary 
Shares.  
Indemnity and insurance of officers 
The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity as a director 
or executive, for which they may be held personally liable, except where there is a lack of good faith. 
During the financial year, the Company paid a premium in respect of a contract to insure the directors and executives of the 
Company  against  a  liability  to  the  extent  permitted  by  the  Corporations  Act  2001.  The  contract  of  insurance  prohibits 
disclosure of the nature of the liability and the amount of the premium. 
Proceedings on behalf of the Company  
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf 
of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility 
on behalf of the Company for all or part of those proceedings. 
Indemnity and insurance of auditor 
The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the 
Company or any related entity against a liability incurred by the auditor. 
During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company 
or any related entity. 
17 
 
  
  
  
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
  
  
 
 
 
  
Nanollose Limited Directors' report 30 June 2020      18 Non-audit services Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in Note 16 to the financial statements.   The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.   The directors are of the opinion that the services as disclosed in Note 16 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:   - all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and   - none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.   Corporate Governance The Company’s 2020 Corporate Governance Statement is contained in the ‘Corporate Governance’ section of the Company’s website at https://nanollose.com/about/corporate-governance/.  Auditor's independence declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors’ report.  Auditor RSM Australia Partners continues in office in accordance with Section 327 of the Corporations Act 2001.      This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.   On behalf of the directors          Winton Willesee Director   25 August 2020 Perth   RSM Australia Partners
Level 32, Exchange Tower 
2 The Esplanade Perth WA 6000
GPO Box R1253 Perth WA 6844
T +61 (0) 8 9261 9100 
F +61 (0) 8 9261 9111 
www.rsm.com.au 
AUDITOR’S INDEPENDENCE DECLARATION 
As  lead  auditor  for  the  audit  of  the  financial  report  of  Nanollose  Limited  for  the  year  ended  30  June  2020,  I 
declare that, to the best of my knowledge and belief, there have been no contraventions of: 
(i) 
(ii) 
the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and 
any applicable code of professional conduct in relation to the audit. 
RSM AUSTRALIA PARTNERS 
Perth, WA 
Dated: 25 August 2020 
TUTU PHONG 
Partner 
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
RSM Australia Partners is a member of the RSM network and trades as RSM.  RSM is the trading name used by the members of the RSM network.  Each member of the RSM network is an independent 
accounting and consulting firm which practices in its own right.  The RSM network is not itself a separate legal entity in any jurisdiction. 
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
Nanollose Limited 
Statement of profit or loss and other comprehensive income 
For the year ended 30 June 2020 
  Note   
2020 
$ 
2019 
$ 
Revenue 
Interest income 
R&D incentives 
Government Grant – Cashflow Boost 
Expenses 
Research expenses 
Promotion and communication expenses 
Consultancy and legal expenses 
Employee benefits expense 
Depreciation expense                                                                                                         
Share-based payments                         
Other expenses 
Interest expense 
Loss before income tax expense  
Income tax expense 
           5,830 
       461,847 
       100,000 
       567,677 
          50,462 
        235,846 
                   - 
        286,308 
      (474,557)   
        (66,311)   
      (171,651)   
      (636,307)   
        (53,526)   
     (235,538)   
      (161,737)   
          (3,539)   
    (725,411)
    (112,052)
    (343,119)
    (835,128)
      (32,158)
      (39,178) 
    (197,578) 
        (5,679) 
   (1,235,489)        (2,003,995) 
4 
                  - 
                - 
Loss after income tax expense for the year 
   (1,235,489)       (2,003,995)  
Other comprehensive income for the year, net of tax 
              -  
                   -  
Total comprehensive loss for the year 
   (1,235,489)        (2,003,995)  
Basic loss per share 
Diluted loss per share 
Cents 
Cents 
  24 
  24 
  1.57 
  1.57 
  2.67 
  2.67 
The above statement of profit or loss and other comprehensive income should be read in conjunction with the 
accompanying notes 
20 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Nanollose Limited 
Statement of financial position 
As at 30 June 2020 
Assets 
Current assets 
Cash and cash equivalents 
Trade and other receivables 
Prepayments 
Total current assets 
Non-current assets 
Right of use asset 
Plant and equipment 
Total non-current assets 
Total assets 
Liabilities 
Current liabilities 
Trade and other payables 
Provisions 
Lease liability 
Borrowings 
Total current liabilities 
Non-current liabilities 
Lease liability 
Total current liabilities 
Total liabilities 
Net assets 
Equity 
Issued capital 
Reserves 
Accumulated losses 
Total equity 
5 
6 
7 
8 
9 
  10 
  11 
  11 
  12 
  13 
  14 
2020 
$ 
        2019 
$ 
     839,161   
       67,372   
       22,930   
     929,463   
   1,122,710 
        30,878 
        40,875 
   1,194,463 
       35,519   
       56,988   
       92,507   
                 - 
        83,320 
        83,320 
  1,021,970   
   1,277,783 
     147,161   
       31,467   
       26,424   
       20,295   
     225,347   
      115,580 
        42,638 
                 - 
                 - 
      158,218 
       11,405   
       11,405   
                 - 
                 - 
     236,752   
      158,218 
     785,218   
   1,119,565 
  5,788,186   
     801,086   
 (5,804,054)    
   5,120,207 
      565,548 
  (4,566,190) 
     785,218   
   1,119,565 
The above statement of financial position should be read in conjunction with the accompanying notes 
21 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
             
 
 
  
 
 
 
 
  
 
 
 
  
  
 
 
  
 
  
 
 
   
 
 
  
 
 
 
  
 
 
  
 
 
  
      
 
      
 
  
 
  
 
 
  
 
 
 
  
 
 
 
 
 
  
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
  
  
  
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
  
  
 
 
  
 
 
 
  
 
 
 
  
  
  
 
 
 
  
 
 
 
 
 
  
  
  
Nanollose Limited 
Statement of changes in equity 
For the year ended 30 June 2020 
Issued 
Capital 
$ 
Reserves 
$ 
Accumulated 
Losses 
$ 
Total 
Equity 
$ 
Balance as at 1 July 2019 
   5,120,207 
    565,548 
   (4,566,190)      1,119,565 
Adjustment to accumulated losses at 1 July 2019 arising from 
the adoption of AASB16 Leases 
          (2,375)            (2,375) 
Total comprehensive loss for the year 
              - 
            - 
   (1,235,489)     (1,235,489) 
Transactions with owners in their capacity as owners: 
Contributions of equity, net of transaction costs 
Share based payments (note 12b) 
      667,979 
             - 
               - 
    235,538 
               - 
                  - 
       667,979 
       235,538 
Balance as at 30 June 2020 
   5,788,186 
    801,086 
   (5,804,054)         785,218 
Issued 
Capital 
$ 
Reserves 
$ 
Accumulated 
Losses 
$ 
Total 
Equity 
$ 
Balance as at 1 July 2018 
   5,120,537 
    483,928 
   (2,562,195)      3,042,270 
Total comprehensive loss for the year 
                 - 
               - 
   (2,003,995)     (2,003,995) 
Transactions with owners in their capacity as owners: 
Contributions of equity, net of transaction costs 
Share based payments (note 12b) 
Issue of options (note 12a) 
           (330) 
                 - 
                 - 
               - 
      39,178 
      42,442 
                  - 
                  - 
                  - 
             (330) 
         39,178 
         42,442 
Balance as at 30 June 2019 
   5,120,207 
    565,548 
   (4,566,190)      1,119,565 
The above statement of changes in equity should be read in conjunction with the accompanying notes 
22 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Nanollose Limited 
Statement of cash flows 
For the year ended 30 June 2020 
Cash flows from operating activities 
Payments to suppliers and employees 
Interest received 
Interest paid 
R&D incentive received 
Government grants received – Cashflow Boost 
  Note   
2020 
$ 
2019 
$ 
   (1,462,442)     (2,154,663) 
           8,540 
         56,249 
          (3,539)                    - 
       235,846 
       461,847 
                  - 
         50,000 
Net cash used in operating activities 
  22 
      (945,594)     (1,862,568) 
Cash flows from investing activities 
Payments for plant and equipment 
Net cash used in investing activities 
Cash flows from financing activities 
Proceeds from issue of shares 
Share issue costs 
Proceeds from issue of options 
Proceeds from borrowings 
Repayment of borrowings 
Repayment of lease liability  
Net cash from financing activities 
          (1,091)          (37,209) 
          (1,091)          (37,209) 
        720,000                    - 
        (52,021)               (330) 
         42,442 
                  - 
         33,825 
                  - 
       (13,530)                    - 
    (25,138)                    - 
        663,136           42,112 
Net (decrease) in cash and cash equivalents 
Cash and cash equivalents at the beginning of the financial year 
Cash and cash equivalents at the end of the financial year 
5 
     (283,549)          
    1,122,710 
(1,857,665)          
  2,980,375 
  2,940,164          
       839,161         
  1,122,710         
  2,980,375         
The above statement of cash flows should be read in conjunction with the accompanying notes 
23 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
   
 
 
 
 
 
 
          
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
     
 
 
 
       
 
 
 
 
  
 
 
 
 
  
Nanollose Limited
Notes to the financial statements
30 June 2020
Note 1. Significant accounting policies 
The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies 
have been consistently applied to all the years presented, unless otherwise stated. 
New or amended Accounting Standards and Interpretations adopted 
The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian 
Accounting Standards Board that are mandatory for the current reporting period. The impact on the financial performance 
and position of the Company from the adoption of the new or amended Accounting Standards and Interpretations was not 
material.  Any  new  or  amended  Accounting  Standards  or  Interpretations  that  are  not  yet  mandatory  have  not  been  early 
adopted. 
Basis of preparation 
These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards and 
Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate 
for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as 
issued by the International Accounting Standards Board ('IASB'). 
Historical cost convention 
The  financial  statements  have  been  prepared  under  the  historical  cost  convention,  except  for,  where  applicable,  certain 
financial assets and liabilities. 
Critical accounting estimates 
The  preparation  of  the  financial  statements  requires  the  use  of  certain  critical  accounting  estimates.  It  also  requires 
management to exercise its judgement in the process of applying the Company’s accounting policies. The areas involving a 
higher  degree  of  judgement  or  complexity,  or  areas  where  assumptions  and  estimates  are  significant  to  the  financial 
statements, are disclosed in note 2. 
Going concern  
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business 
activities and the realisation of assets and discharge of liabilities in the normal course of business. 
As disclosed in the financial statements, the Company incurred a loss of $1,235,489 and had net cash outflows from operating 
activities of $945,594 for the year ended 30 June 2020.
The  Directors  believe  that  it  is  reasonably  foreseeable  that  the  Company  will  continue  as  a  going  concern  and  that  it  is 
appropriate  to  adopt  the  going  concern  basis  in  the  preparation  of  the  financial  report  after consideration  of the following 
factors:   
1.  The Company had cash and cash equivalents at 30 June 2020 of $839,161; 
2.  The Company expects to receive a R&D tax incentive during the year ended 30 June 2021 upon lodgement of its claim; 
3.  The  Company’s  business  model  includes  strategies  to  secure  cash  flows  from  commercial  sales  of  the  Company’s 
nullarbor™ and other products; 
4.  The Company has the ability to issue additional equity securities under the Corporations Act 2001 to raise further working 
capital; and  
5.  The Company has the ability to curtail administrative, discretionary research expenses and overhead cash outflows as 
and when required. 
Operating segments 
Operating segments are presented using the ‘management approach’, where the information presented is on the same basis 
as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation 
of resources to operating segments and assessing their performance. 
Foreign currency translation 
The  financial  statements  are  presented  in  Australian  dollars,  which  is  Nanollose  Limited’s  functional  and  presentation 
currency. 
24 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
Foreign currency transactions 
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the 
transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation 
at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in 
profit or loss.  
Revenue recognition 
Interest 
Interest income is recognised as interest accrues using the effective interest method. This is a method of calculating the 
amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, 
which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the 
net carrying amount of the financial asset. 
Other revenue 
Other revenue is recognised when it is received or when the right to receive payment is established. 
Income tax 
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable 
income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary 
differences, unused tax losses and the adjustment recognised for prior periods, where applicable. 
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the 
assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: 
 When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a
● 
transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor 
taxable profits; or 
 When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the 
timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable 
future. 
● 
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that 
future taxable amounts will be available to utilise those temporary differences and losses. 
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax 
assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the 
carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable 
that there are future taxable profits available to recover the asset. 
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against 
current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on 
either the same taxable entity or different taxable entities which intend to settle simultaneously. 
Earnings per share 
Basic earnings per share 
Basic earnings per share is calculated by dividing the profit attributable to the owners of the Company, excluding any costs 
of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the 
financial year, adjusted for bonus elements in ordinary shares issued during the financial year. 
Diluted earnings per share 
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the 
after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted 
average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. 
25 
 
  
  
  
 
  
  
  
  
  
  
  
  
  
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
Current and non-current classification 
Assets and liabilities are presented in the statement of financial position based on current and non-current classification. 
An  asset  is  classified  as  current  when:  it  is  either  expected  to  be  realised  or  intended  to  be  sold  or  consumed  in  the 
Company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months 
after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a 
liability for at least 12 months after the reporting period. All other assets are classified as non-current. 
A liability is classified as current when: it is either expected to be settled in the Company's normal operating cycle; it is held 
primarily  for  the  purpose  of  trading;  it  is  due  to  be  settled  within  12  months  after  the  reporting  period;  or  there  is  no 
unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities 
are classified as non-current. 
Cash and cash equivalents 
Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly 
liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and 
which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash 
and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement 
of financial position. 
Trade and other receivables 
Trade  receivables  are  initially  recognised  at  fair  value  and  subsequently  measured  at  amortised  cost  using  the  effective 
interest method, less any provision for impairment. Trade receivables are generally due for settlement within 30 days. 
The Company has applied the simplified approach of measuring expected credit losses, which uses a lifetime expected loss 
allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue. 
Other receivables are recognised at amortised cost, less any allowance for expected credit losses. 
Plant and equipment 
Plant  and  equipment  is  stated  at  historical  cost  less  accumulated  depreciation  and  impairment.  Historical  cost  includes 
expenditure that is directly attributable to the acquisition of the items. 
Depreciation is calculated on a straight-line or diminishing balance basis to write off the net cost of each class of plant and 
equipment over their expected useful lives as follows: 
Plant and equipment 
Leasehold improvements 
3-5 years 
4 years 
diminishing balance 
stright-line  
The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. 
Leasehold improvements and plant and equipment under lease are depreciated over the unexpired period of the lease or 
the estimated useful life of the assets, whichever is shorter. 
An item of plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Company. 
Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation surplus 
reserve relating to the item disposed of is transferred directly to retained profits. 
26 
 
  
  
  
  
  
  
  
 
 
  
  
  
 
 
  
  
  
  
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
Right-of-use assets 
A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which 
comprises the  initial  amount of the lease liability, adjusted for, as  applicable,  any lease payments  made  at or  before the 
commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the 
cost of inventories, an estimate of costs expected to  be incurred for dismantling and removing the underlying asset, and 
restoring the site or asset. 
Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful 
life of the asset, whichever is the shorter. Where the company expects to obtain ownership of the leased asset at the end of 
the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for 
any remeasurement of lease liabilities. 
The company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with 
terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss 
as incurred. 
Trade and other payables 
These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year 
and which are  unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The 
amounts are unsecured and are usually paid within 30 days of recognition. 
Employee benefits 
Short-term employee benefits 
Liabilities  for  wages  and  salaries,  including  non-monetary  benefits,  annual  leave  and  long  service  leave  expected  to  be 
settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities 
are settled. 
Other long-term employee benefits 
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are 
measured at the present value of expected future payments to be made in respect of services provided by employees up to 
the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, 
experience of employee departures and periods of service. Expected future payments are discounted using market yields at 
the reporting date on corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated 
future cash outflows. 
Share-based payments 
Equity-settled and cash-settled share-based compensation benefits are provided to employees. 
Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the 
rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash 
is determined by reference to the share price. 
The cost of equity-settled transactions is measured at fair value on grant date. Fair value is independently determined using 
either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, 
the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend 
yield  and the risk free interest rate for the term of the option, together with non-vesting conditions that do  not  determine 
whether the Company receives the services that entitle the employees to receive payment. No account is taken of any other 
vesting conditions. 
The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over the vesting 
period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate 
of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit 
or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous 
periods. 
27 
 
  
  
  
 
 
 
  
  
  
  
  
  
  
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the 
Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was 
granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows: 
- 
- 
during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied 
by the expired portion of the vesting period. 
from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at 
the reporting date. 
All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to 
settle the liability. 
Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions 
are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are 
satisfied. 
If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An 
additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value 
of the share-based compensation benefit as at the date of modification. 
If the non-vesting condition is within the control of the Company or employee, the failure to satisfy the condition is treated as 
a cancellation. If the condition is not within the control of the Company or employee and is not satisfied during the vesting 
period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited. 
If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense 
is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award 
is treated as if they were a modification. 
Lease liabilities 
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present 
value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, 
if  that  rate  cannot  be  readily  determined,  the  company's  incremental  borrowing  rate.  Lease  payments  comprise  of  fixed 
payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected 
to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably 
certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or 
a rate are expensed in the period in which they are incurred. 
Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured 
if  there  is  a  change  in  the  following:  future  lease  payments  arising  from  a  change  in  an  index  or  a  rate  used;  residual 
guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an 
adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset 
is fully written down. 
Finance costs 
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in 
the period in which they are incurred. 
Borrowings 
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They 
are subsequently measured at amortised cost using the effective interest method. 
Fair value measurement 
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair 
value  is based  on the price that would be received to sell  an asset or paid to transfer a liability in an orderly transaction 
between market participants at the measurement date; and assumes that the transaction will take place either: in the principal 
market; or in the absence of a principal market, in the most advantageous market. 
28 
 
  
  
  
 
 
 
 
  
  
  
  
  
  
  
  
 
 
  
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming 
they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and 
best  use.  Valuation  techniques  that  are  appropriate  in  the  circumstances  and  for  which  sufficient  data  are  available  to 
measure fair value, are used,  maximising the use of  relevant observable  inputs  and minimising the use of  unobservable 
inputs. 
Assets  and  liabilities  measured  at  fair  value  are  classified  into  three  levels  using  a  fair  value  hierarchy  that  reflects  the 
significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers 
between  levels  are  determined  based  on  a  reassessment  of  the  lowest  level  of  input  that  is  significant  to  the  fair  value 
measurement. 
For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not 
available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and 
reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is 
undertaken,  which  includes  a  verification  of  the  major  inputs  applied  in  the  latest  valuation  and  a  comparison,  where 
applicable, with external sources of data. 
Issued capital 
Ordinary shares are classified as equity. 
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, 
from the proceeds. 
Dividends 
Dividends are recognised when declared during the financial year and no longer at the discretion of the Company. 
Goods and Services Tax ('GST') and other similar taxes 
Revenues,  expenses  and  assets  are  recognised  net  of  the  amount  of  associated  GST,  unless  the  GST  incurred  is  not 
recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of 
the expense. 
Receivables  and  payables  are  stated  inclusive  of  the  amount  of  GST  receivable  or  payable.  The  net  amount  of  GST 
recoverable  from,  or  payable  to,  the  tax  authority  is  included  in  other  receivables  or  other  payables  in  the  statement  of 
financial position. 
Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities 
which are recoverable from, or payable to the tax authority, are presented as operating cash flows. 
Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. 
New or amended Accounting Standards and Interpretations adopted 
The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian 
Accounting Standards Board ('AASB') that are mandatory for the current reporting period.  
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. 
The following Accounting Standards and Interpretations are most relevant to the company: 
AASB 16 Leases 
The company has adopted AASB 16 from 1 July 2019. The standard replaces AASB 117 'Leases' and for lessees eliminates 
the classifications of operating leases and finance leases. Except for short-term leases and leases of low-value assets, right-
of-use assets and corresponding lease liabilities are recognised in the statement of financial position. Straight-line operating 
lease expense recognition is replaced with a depreciation charge for the right-of-use assets (included in operating costs) and 
an  interest expense on the recognised  lease  liabilities (included in finance costs). In  the earlier  periods  of the  lease, the 
expenses associated with the lease under AASB 16 will be higher when compared to lease expenses under AASB 117.  
29 
 
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 1. Significant accounting policies (continued) 
However, EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) results improve as the operating expense 
is now replaced by interest expense and depreciation in profit or loss. For classification within the statement of cash flows, 
the interest portion is disclosed in operating activities and the principal portion of the lease payments are separately disclosed 
in financing activities. For lessor accounting, the standard does not substantially change how a lessor accounts for leases. 
Impact of adoption  
AASB 16 was adopted using the modified retrospective approach and as such the comparatives have not been restated. 
The impact of adoption on opening retained profits as at 1 July 2019 was as follows: 
Operating lease commitments as at 1 July 2019 (AASB 117) 
Operating lease commitments discount based on the weighted average incremental borrowing rate of 5% 
(AASB 16) 
Accumulated depreciation as at 1 July 2019 (AASB 16) 
Right-of-use assets (AASB 16) 
Lease liabilities - current (AASB 16) 
Lease liabilities - non-current (AASB 16) 
Reduction in opening retained profits as at 1 July 2019 
  1 July 2019 
$ 
110,400 
(10,111)
(39,698)
60,591 
(25,138)
(37,829)
(2,375)
New Accounting Standards and Interpretations not yet mandatory or early adopted 
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, 
have  not  been  early  adopted  by  the  Company  for  the  annual  reporting  period  ended  30  June  2020.  The  Company’s 
assessment  of  the  impact  of  these  new  or  amended  Accounting  Standards  and  Interpretations,  most  relevant  to  the 
Company, are set out below. 
Conceptual Framework for Financial Reporting (Conceptual Framework) 
The revised Conceptual Framework is applicable to annual reporting periods beginning on or after 1 January 2020 and early 
adoption is permitted. The Conceptual Framework contains new definition and recognition criteria as well as new guidance 
on measurement that affects several Accounting Standards. Where the Company has relied on the existing framework in 
determining its accounting policies for transactions, events or conditions that are not otherwise dealt with under the Australian 
Accounting Standards, the consolidated entity may need to review such policies under the revised framework. At this time, 
the  application  of  the  Conceptual  Framework  is  not  expected  to  have  a  material  impact  on  the  Company's  financial 
statements. 
30 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 2. Critical accounting judgements, estimates and assumptions 
The  preparation  of  the  financial  statements  requires  management  to  make  judgements,  estimates  and  assumptions  that 
affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in 
relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and 
assumptions  on historical  experience  and on  other various factors, including expectations of future  events, management 
believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal 
the  related  actual  results.  The  judgements,  estimates  and  assumptions  that  have  a  significant  risk  of  causing  a  material 
adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are 
discussed below. 
Share-based payment transactions 
The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity 
instruments at the date at which they are granted. Management has applied a probability estimate to the vesting conditions 
being  met,  since  the  Company  was  unable  to  reliably  measure  the  fair  value  of  the  services  received.  The  accounting 
estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts 
of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.  
Note 3. Operating segments 
Primary Reporting Format – Business Segments 
The  Company  has  one  geographical  location  which  is  Australia.  The  Company’s  sole  operations  are  research  and 
development, and promotion of the Company’s nanocellulose technology from that location. 
Identification of reportable operating segments 
The  operating  segment  identified  is  based  on  the  internal  reports  that  are  reviewed  and  used  by  the  Directors  (who  are 
identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of 
resources.  There  is  no  aggregation  of  operating  segments.  The  CODM  reviews  EBITDA  (Earnings  Before  Interest,  Tax, 
Depreciation and Amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those 
adopted in the financial statements. The information reported to the CODM is on at least a quarterly basis. 
Note 4. Income tax expense 
Reconciliation of income tax expense and tax at the statutory rate 
Loss before income tax expense from continuing operations 
Tax benefit at the statutory tax rate of 27.5%  
Tax effect amounts which are not deductible/(taxable) in calculating taxable income: 
Other non-deductible expenses 
Future tax benefit not recognised 
Income tax expense 
2020 
$ 
2019 
$ 
   (1,235,489)   
   (2,003,995) 
       339,759   
       551,098 
        (65,178)   
       274,581   
        (11,021) 
       540,077 
      (274,581)   
      (540,077) 
                   -    
                  -  
31 
 
  
  
  
  
 
  
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 4. Income tax expense (continued) 
Unrecognised deferred tax balances 
The  Company  does  not  currently  recognise  any  deferred  tax  asset  arising  from  its  accumulated  losses.  The  Directors 
estimate that the potential deferred tax assets at 27.5% not brought to account attributable to tax losses carried forward at 
reporting date is approximately $906,067 (2019: $631,486).  
The losses have not been brought to account because the Directors do not believe it is appropriate to regard realisation of 
those deferred tax assets as being probable. The benefit of these deferred tax assets will only be obtained if: 
(1) 
(2) 
(3) 
the Company derives future assessable income of a nature and of an amount sufficient to enable the benefit from 
the deductions for the temporary differences to be realised; 
the Company continues to comply with the conditions for deductibility imposed by tax legislation; and 
no  changes  in  tax  legislation  adversely  affect  the  Company  in  realising  the  benefit  from  the  deductions  for  the 
temporary differences. 
Note 5. Cash and cash equivalents 
Cash at bank 
Term deposit [1] 
[1] – Term deposit amount includes $20,000 used as security for credit cards. 
Note 6. Trade and other receivables 
ATO receivables 
Accrued interest 
Note 7. Right of use asset 
Right of use asset 
Accumulated depreciation 
Right of use asset 
Opening balance 
Transitional adjustment for adoption of AASB16 
Closing balance  
Accumulated depreciation 
Opening balance 
Transitional adjustment for adoption of AASB16 
Depreciation expense 
32 
2020 
$ 
2019 
$ 
        269,161          252,710 
        570,000          870,000 
        839,161       1,122,710 
          66,886   
               486   
      27,682 
        3,196 
          67,372   
      30,878 
        100,289   
         (64,770)   
               - 
               - 
          35,519   
               - 
                   - 
        100,289 
               - 
               - 
        100,289   
               - 
                   - 
         (39,698)   
         (25,072)   
               - 
               - 
               - 
         (64,770)   
               - 
 
  
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
 
 
  
 
 
 
 
  
 
  
 
 
 
  
  
 
  
 
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
  
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 8.  Plant and Equipment 
Plant and equipment – at cost 
Accumulated depreciation 
Leasehold improvements – at cost 
Accumulated depreciation 
2020 
$ 
2019 
$ 
        65,128 
       (40,855) 
        24,273 
        64,037 
       (24,337) 
        39,700 
        58,251 
       (25,536) 
        32,715 
        58,251 
       (14,631) 
        43,620 
       56,988 
       83,320 
Reconciliations 
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out 
below: 
Balance at 30 June 2018 
Additions 
Disposals 
Depreciation expense 
Balance at 30 June 2019 
Additions 
Disposals 
Depreciation expense 
  Plant and 
  equipment 
$ 
  Leasehold 
  improvements  
$ 
Total 
$ 
       24,494  
       32,936 
                - 
      (17,730) 
         53,775            78,269  
           4,273            37,209  
                  - 
        (14,428)          (32,158) 
                  - 
       39,700  
         1,091 
                - 
      (16,518) 
         43,620            83,320  
           1,091  
                  -  
                  - 
                  - 
        (10,905)          (27,423) 
Balance at 30 June 2020 
      24,273  
        32,715  
        56,988  
Note 9. Trade and other payables 
Trade payables 
Other payables 
Refer to Note 23 for further information on financial instruments. 
2020 
$ 
2019 
$ 
      139,798 
          7,363 
        85,285 
        30,295 
     147,161 
     115,580 
33 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 10. Provisions 
Provision for annual leave 
2020 
$ 
2019 
$ 
       31,467 
     42,638 
Amounts not expected to be settled within the next 12 months 
The current provision for employee benefits includes all unconditional entitlements where employees have completed the 
required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The 
entire amount is presented as current since the Company does not have an unconditional right to defer settlement. 
Note 11. Lease liability 
Lease liability - current 
Lease liability – non-current 
      26,424 
            - 
      11,405 
            - 
The lease liability relates to the lease of premises with an annual; rental of $27,600 and an expiry date of 25 November 
2021.  The portion of the lease liability that relates to the financial year ended 30 June 2021 has been classified as current 
liability and the balance has been classified as non-current. 
Note 12. Equity - issued capital 
2020 
Shares 
2019 
Shares 
2020 
$ 
2019 
$ 
Ordinary shares - fully paid 
  105,749,991    74,999,993       5,788,186    5,120,537 
 Movements in ordinary share capital 
Balance as at 30 June 2018 
Date 
  Shares 
    74,999,993 
  Issue price   
$ 
    5,120,537 
Transaction costs relating to share issues 
                  - 
            (330) 
Balance as at 30 June 2019 
  74,999,993 
    5,120,207 
Issue of shares - rights issue  
Issue of shares – rights issue shortfall  
Issue of shares - lieu of cash fees for advisors  
Transaction costs relating to share issues 
Share based payments 
11 May 2020 
21 May 2020 
21 May 2020 
 15,670,713  
 14,329,285  
750,000 
                  - 
$0.024 
$0.024 
$0.024 
      376,097 
343,903 
18,000 
       (70,021) 
                 - 
Balance as at 30 June 2020 
  105,749,991 
    5,788,186 
Ordinary shares 
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in 
proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the 
Company does not have a limited amount of authorised capital. 
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each 
share shall have one vote. 
34 
 
  
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
                  
 
 
  
 
 
 
 
  
 
 
  
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 13. Equity - reserves 
Options reserve (a) 
Performance rights reserve (b) 
(a) Movements in options reserve 
Balance as at 30 June 2018 
2020 
$ 
       472,945    
       328,141 
2019 
$ 
  472,945  
    92,603 
       801,086 
      565,548 
No. of Options 
      $ 
         41,589,066 
       430,503 
17 August 2018          Issue of 4,244,266 NC6O Listed 
           4,244,266 
       42,442 
Balance as at 30 June 2019 
30 September 2019   lapsed 1,100,000 Class B       
21 May 2020              Issue of 1,000,000 NC6OPT1[1] 
Balance as at 30 June 2020 
         45,833,332 
       472,945 
       (1,100,0000)     
           1,000,000 
                  - 
                  - 
         45,733,332 
       472,945 
[1] These options are free attaching to the issue of shares lieu of cash fees for advisors in relation to the rights issue undertaken in May 2020, hence no value has been attributed to the 
options.  
The options on issue as at 30 June 2020 are as follows: 
   Date of issue 
Class of option 
No. of Options 
Exercise price 
Expiry date 
   4 August 2016 
   5 April 2017 
   5 April 2017 
   5 April 2017 
   21 April 2017 
   21 June 2017 
   21 June 2017 
   25 May 2018 
   17 August 2018 
   21 May 2020 
   Total 
Class A 
Class A 
Class C 
Class D 
Class A 
Class C 
Class D 
         NC6O 
         NC6O 
      NC6OPT1 
      21,000,000 
        1,450,000 
           900,000 
           900,000 
        1,333,333 
           200,000 
           200,000 
      14,505,733 
        4,244,266 
        1,000,000 
      45,733,332 
$0.30 
$0.30 
$0.30 
$0.40 
$0.30 
$0.30 
$0.40 
         $0.30 
         $0.30 
         $0.10 
31 December 2020 
31 December 2020 
30 September 2020 
30 September 2021 
31 December 2020 
30 September 2020 
30 September 2021 
31 December 2020 
31 December 2020 
31 May 2023 
35 
 
  
 
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
           
 
 
   
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 13. Equity – reserves (continued) 
(b) Movements in performance rights reserve 
Balance as at 30 June 2018 
No. of 
Performance 
Rights 
$ 
500,000
53,425 
A & B Class Performance rights- expense recognised for the year end 30 June 2019 
- 
39,178 
Balance as at 30 June 2019 
500,000 
92,603 
B Class Performance rights- expense recognised for the year end 30 June 2020 
C Class Performance rights issued- expense recognised for the year end 30 June 2020 
- 
      4,000,000 
7,397 
      228,141 
Balance as at 30 June 2020 
4,500,000 
328,141 
30 June 2020 - Share based payments  
During  the  year  ended  30  June  2018,  Mr  Alfie  Germano  was  issued  500,000  performance  rights  in  accordance  with  his 
employment contract.  The fair value of the performance rights recognised as an expense (based on the Company share 
price at the grant date and amortised over the vesting period) was measured at $7,397 (2019: $39,178). 
On 20 November 2019, Mr Alfie Germano was issued 2,000,000 performance rights and Dr Wayne Best was issued with 
2,000,000 performance rights pursuant to Shareholder approval at the 2019 Annual General Meeting.  
The performance right will, at the election of the holder, vest and convert into one share if, before 31 December 2020, the 
Company enters into a commercial agreement relating to the licencing of the Company’s intellectual property and receives 
$1,000,000 of gross revenue under this agreement or a Takeover Event occurs. 
The fair value of the performance rights recognised as an expense (based on the Company share price at the grant date and 
amortised over the vesting period) the expenses recognised for the year ended 30 June 2020 was $228,141. 
Note 14. Equity – Accumulated losses 
Accumulated losses at the beginning of the financial year 
Adjustment on 1 July 2019 arising from the adoption of AASB16 Leases 
Loss after income tax expense for the year 
2020 
$ 
2019 
$ 
   (4,566,190)    (2,562,195) 
          (2,375)   
                - 
   (1,235,489)    (2,003,995) 
Accumulated losses at the end of the financial year 
  (5,804,054) 
(4,566,190) 
36 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
             
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 15. Key management personnel compensation 
Key management personnel remuneration has been included in the Remuneration Report section of the Directors’ Report. 
Short-term employee benefits 
Post-employment benefits 
Annual leave payments 
Share-based payments - shares 
Share-based payments - performance rights 
2020 
$ 
2019 
$ 
         537,459            722,646 
           40,964              57,950 
           31,467                       - 
             8,494                       - 
         235,538              39,178 
         853,922            819,774 
Note 16. Remuneration of auditors 
During the financial year the following fees were paid or payable for services provided by RSM Australia Partners, the 
auditor of the Company: 
Audit services – RSM Australia Partners 
Auditor review of the financial statements 
Other services – RSM Australia Partners 
Preparation of income tax return 
Other services 
      28,500
      28,500 
     4,500
        -
4,500
        4,500 
        2,000 
       6,500 
33,000
35,000 
Note 17. Commitments  
The Company has no lease commitments not recognised as liabilities as at 30 June 2020.  
Note 18. Contingent assets  
The Company has no contingent assets as at 30 June 2020 (2019: $nil). 
Note 19. Contingent liabilities 
The Company has no contingent liabilities as at 30 June 2020 (2019: $nil).  
37 
 
  
 
  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 20. Events after the reporting period 
The World Health Organisation announced that the Coronavirus (COVID-19) had become a pandemic on 11 March 2020. 
The impact of the Coronavirus (COVID-19) pandemic is ongoing and whilst it has had no financial impact for the Group up 
to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the re-porting date.  
The situation is rapidly developing and is dependent on measures imposed by the Australian Government and Governments 
of  other  countries,  such  as  maintaining  social  distancing  requirements,  quarantine,  travel  restrictions  and  any  economic 
stimulus that may be provided. The full impact of COVID-19 and timing of easing of restrictions continues to evolve. At the 
date of this report, it is uncertain what the effect will be on the group and potentially it will have a post balance date impact. 
Other  than  the  above,  no  matter  or  circumstance  has  arisen  since  30  June  2020  that  has  significantly  affected,  or  may 
significantly  affect  the  Company's  operations,  the  results  of  those  operations,  or  the  Company's  state  of  affairs  in  future 
financial years.  
Note 21. Related Party Transactions 
Key management personnel 
Disclosures relating to key management personnel are set out in Note 15 and the Remuneration Report included in the 
Directors’ Report. 
Transactions between related parties are on normal commercial terms and conditions no more favourable than those 
available to other parties unless otherwise stated.  
There were no further transactions with Directors or other Key Management Personnel, including their personally related 
parties, not disclosed in Note 15 or the Remuneration Report. 
Note 22. Reconciliation of loss after income tax to net cash used in operating activities 
Loss after income tax expense for the year 
Adjustments for: 
Depreciation of plant and equipment 
Depreciation of right-of-use-asset  
Performance rights 
Change in operating assets and liabilities: 
Trade and other receivables 
Other current assets 
Provisions 
Trade and other payables 
Net cash used in operating activities 
2020 
$ 
2019 
$ 
   (1,235,489)       (2,003,995) 
         27,423             32,158 
- 
       235,538             39,178 
       25,072 
        (36,494)             12,320 
         17,947             59,927 
        (11,172)            28,484 
         31,581           (30,640) 
      (945,594)        (1,862,568) 
38 
 
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 23. Financial Instruments 
The Company’s activities are being funded by equity and are not exposed to significant financial risks. 
There are no speculative or financial derivative instruments.  The Company holds the following financial instruments: 
Financial assets 
Cash and cash equivalents 
Trade and other receivables 
Financial liabilities 
Trade and other payables 
Lease liability (current and non-current)  
Borrowings  
2020 
$ 
             839,161 
               67,372 
             906,533 
             143,666 
               37,828 
               20,295 
             201,789 
2019 
$ 
          1,122,710 
               30,878 
          1,153,588 
             115,580 
    - 
- 
             115,580 
The Company’s principal financial instruments comprise of cash. The main purpose of these financial instruments is to fund 
the Company’s operations. 
It is, and has been throughout the period under review, the Company’s policy that no trading in financial instruments shall be 
undertaken.  The main risks arising from the Company’s financial operations are credit risk, capital risk and liquidity risk.  The 
Directors’ review and agree policies for managing each of these risks and they are summarised below: 
(a) 
Credit risk 
Management does not actively manage credit risk as the Company has no significant exposure to credit risk from 
external parties at year end as there are no trade receivables. 
(b) 
Capital risk 
The Company’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that 
it can continue to provide returns for shareholders and benefits  for other stakeholders and to maintain  an  optimal 
capital structure to reduce the cost of capital.  In order to maintain or adjust the capital structure, the Company may 
adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets 
to reduce debt. 
(c) 
Liquidity risk 
Maturity profile of financial instruments   
Prudent liquidity risk management implies maintaining sufficient cash balances and access to equity funding. 
The Company’s exposure to the risk of changes in market interest rates relates primarily to cash assets and floating 
interest  rates.  The  Company  does  not  have  significant  interest-bearing  assets  and  is  not  materially  exposed  to 
changes in market interest rates. 
The Company does not have financial instruments with maturity exceeding 12 months, other than non-current lease 
liability repayments of $11,405 from the reporting date as at 30 June 2020 (2019 nil exceeding 12 months).  
 Sensitivity analysis – interest rates 
 The sensitivity effect of possible interest rate movements has not been disclosed as they are insignificant. 
(d) 
Net fair value of financial assets and liabilities 
 Unless otherwise stated, the carrying amount of financial instruments reflect their fair value.  
39 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanollose Limited 
Notes to the financial statements 
30 June 2020 
Note 24. Loss per share  
Basic loss per share (cents) 
Diluted loss per share (cents) 
Net loss used in the calculation of basic and diluted loss per share 
Weighted average number of ordinary shares outstanding during the year used in 
the calculation of basic loss per share 
Weighted average number of ordinary shares outstanding during the year used in 
the calculation of diluted loss per share 
2020 
cents 
       1.57  
       1.57 
2019 
cents 
       2.67  
       2.67  
2020 
$ 
(1,235,489)  
2019 
$ 
 (2,003,995) 
78,713,323 
74,999,993 
78,713,323 
74,999,993 
As the Company is in a loss position, the diluted loss per share calculation excludes the dilutive effect of the performance 
rights and options issued and not yet converted to ordinary shares. 
40 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Nanollose Limited Directors' declaration 30 June 2020      41 In the directors' opinion:   (i)  the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;   (ii)  the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board;   (iii)  the attached financial statements and notes give a true and fair view of the Company's financial position as at 30 June 2020 and of its performance for the financial year ended on that date; and   (iv)  there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.     The directors have been given the declarations required by section 295A of the Corporations Act 2001.   Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.   On behalf of the directors       Winton Willesee Director   25 August 2020 Perth    RSM Australia Partners
Level 32, Exchange Tower 
2 The Esplanade Perth WA 6000
GPO Box R1253 Perth WA 6844
T +61 (0) 8 9261 9100 
F +61 (0) 8 9261 9111 
www.rsm.com.au 
INDEPENDENT AUDITOR’S REPORT 
TO THE MEMBERS OF  
NANOLLOSE LIMITED 
Opinion 
We  have  audited  the  financial  report  of  Nanollose  Limited  (the  Company),  which  comprises  the  statement  of 
financial  position  as  at  30  June  2020,  the  statement  of  profit  or  loss  and  other  comprehensive  income,  the 
statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial 
statements, including a summary of significant accounting policies, and the directors' declaration. 
In our opinion, the accompanying financial report of the Company is in accordance with the Corporations Act 2001, 
including:  
(i) 
Giving  a  true  and  fair  view  of  the  Company's  financial  position  as  at  30  June  2020  and  of  its  financial 
performance for the year then ended; and 
(ii) 
Complying with Australian Accounting Standards and the Corporations Regulations 2001. 
Basis for Opinion 
We  conducted  our  audit  in  accordance  with  Australian  Auditing  Standards.  Our  responsibilities  under  those 
standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of 
our report. We are independent of the Company in accordance with the auditor independence requirements of 
the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards 
Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the 
financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.  
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to 
the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's 
report. 
We  believe  that  the  audit  evidence  we  have  obtained  is  sufficient  and  appropriate  to  provide  a  basis  for  our 
opinion. 
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
RSM Australia Partners is a member of the RSM network and trades as RSM.  RSM is the trading name used by the members of the RSM network.  Each member of the RSM network is an independent 
accounting and consulting firm which practices in its own right.  The RSM network is not itself a separate legal entity in any jurisdiction. 
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of 
the financial report of the current period. These matters were addressed in the context of our audit of the financial 
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.  
Key Audit Matter
Going Concern 
Refer to Note 1 to the financial statements
For the year ended 30 June 2020, the Company has 
incurred  a  loss  of  $1,235,489  and  had  net  cash 
outflows from operating activities of $945,594.  
The  directors’  have  prepared  the  financial  report  on 
the going concern basis. The directors’ assessment of 
the Company’s ability to continue as a going concern 
is  based  on  the  factors  disclosed  in  Note  1  to  the 
financial statements.  
to 
The assessment of going concern is a key audit matter 
due 
in 
determining  why  the  adoption  of  the  going  concern 
basis is appropriate. 
the  significant 
judgements 
involved 
How our audit addressed this matter
Our audit procedures included: 
  Assessing 
the  going 
the  appropriateness  of 
concern factors and the mathematical accuracy of 
the cash flow budget prepared by the Company;  
  Challenging 
of 
assumptions used in its cash flow forecast;   
reasonableness 
the 
key 
  Critically assessing the directors’ reasons  of why 
they  believe  it  is  appropriate  to  prepare  the 
financial report on a going concern basis; and  
  Assessing  the  adequacy  of  the  going  concern 
disclosures in the financial report. 
Other Information  
The directors are responsible for the other information. The other information comprises the information included 
in the Company's annual report for the year ended 30 June 2020 but does not include the financial report and the 
auditor's report thereon.  
Our opinion on the financial report does not cover the other information and accordingly we do not express any 
form of assurance conclusion thereon.  
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing 
so, consider whether the other information is materially inconsistent with the financial report or our knowledge 
obtained in the audit or otherwise appears to be materially misstated.  
If,  based  on  the  work  we  have  performed,  we  conclude  that  there  is  a  material  misstatement  of  this  other 
information, we are required to report that fact. We have nothing to report in this regard.  
Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of the financial report that gives a true and fair 
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal 
control as the directors determine is necessary to enable the preparation of the financial report that gives a true 
and fair view and is free from material misstatement, whether due to fraud or error.  
In preparing the financial report, the directors are responsible for assessing the ability of the Company to continue 
as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis 
of  accounting  unless  the  directors  either  intend  to  liquidate  the  Company  or  to  cease  operations,  or  have  no 
realistic alternative but to do so.  
Auditor's Responsibilities for the Audit of the Financial Report
Our  objectives  are  to  obtain  reasonable  assurance  about  whether  the  financial  report  as  a  whole  is  free  from 
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. 
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance 
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements 
can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably 
be expected to influence the economic decisions of users taken on the basis of this financial report.  
A  further  description  of  our  responsibilities  for  the  audit  of  the  financial  report  is  located  at  the  Auditing  and 
Assurance  Standards  Board  website  at:  https://www.auasb.gov.au/auditors_responsibilities/ar2.pdf.  This 
description forms part of our auditor's report.  
Report on the Remuneration Report 
Opinion on the Remuneration Report
We have audited the Remuneration Report included in the directors’ report for the year ended 30 June 2020.  
In our opinion, the Remuneration Report of Nanollose Limited, for the year ended 30 June 2020, complies with 
section 300A of the Corporations Act 2001.  
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration Report 
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the 
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.  
RSM AUSTRALIA PARTNERS 
Perth, WA 
Dated: 25 August 2020  
TUTU PHONG 
Partner 
Shareholder Information 
The shareholder information set out below was applicable as at 1 August 2020. 
1.  Quotation  
Listed securities in Nanollose Limited are quoted on the Australian Securities Exchange under ASX code NC6 (Fully Paid 
Ordinary Shares) and NC6O (Listed Options). 
2.  Voting Rights 
The voting rights attached to the Fully Paid Ordinary shares of the Company are: 
(a) 
(b) 
at a meeting of members or classes of members each member entitled to vote may vote in person or by proxy 
or by attorney; and 
on a show of hands, every person present who is a member has one vote, and on a poll every person present 
in person or by proxy or attorney has one vote for each ordinary share held. 
There are no voting rights attached to any Options or Performance Rights on issue. 
3.  Distribution of Shareholders 
i) 
Fully Paid Ordinary Shares 
Shares Range 
Holders 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
13 
54 
73 
287 
137 
564 
Units 
2,891 
202,271 
626,741 
11,463,162 
93,454,926 
% 
0.01 
0.19 
0.59 
10.84 
88.37 
105,749,991 
100.00% 
On 1 August 2020, there were 101 holders of unmarketable parcels of less than 442,437 ordinary shares (based on the 
closing share price of $0.0520).  
ii) 
Listed Options exercisable at $0.30 on or before 31 December 2020 
Shares Range 
Holders 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
8 
77 
28 
89 
28 
230 
Units 
5,618 
222,495 
202,520 
2,521,166 
15,798,200 
18,749,999 
45 
% 
0.03 
1.19 
1.08 
13.45 
84.26 
100.00% 
  
  
 
 
% 
- 
- 
- 
- 
% 
- 
- 
- 
- 
% 
- 
- 
- 
- 
iii) 
Class A Performance Rights  
Shares Range 
Holders 
Units 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
- 
- 
- 
- 
1 
1 
1Holders who hold more than 20% of securities are: 
Germano McInally Pty Ltd – 250,000 performance rights 
iv) 
Class B Performance Rights  
Shares Range 
Holders 
Units 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
- 
- 
- 
- 
1 
1 
1Holders who hold more than 20% of securities are: 
Germano McInally Pty Ltd – 250,000 performance rights 
v) 
Class C Performance Rights  
Shares Range 
Holders 
Units 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
- 
- 
- 
- 
2 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
250,0001 
250,000 
100.00 
100.00% 
250,0001 
250,000 
100.00 
100.00% 
4,000,0001 
4,000,000 
100.00 
100.00% 
1Holders who hold more than 20% of securities are: 
Wayne Morris Best 
Continue reading text version or see original annual report in PDF format above